Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 2
1967 5
1968 6
1969 1
1970 1
1972 5
1973 1
1974 1
1977 2
1978 1
1979 2
1980 1
1981 1
1983 2
1984 1
1986 1
1991 1
1992 9
1993 1
1996 1
1997 2
1998 1
1999 5
2000 6
2001 1
2002 1
2003 2
2004 1
2005 1
2006 1
2007 1
2008 3
2009 1
2010 4
2011 4
2012 4
2013 2
2014 3
2015 2
2016 2
2017 4
2018 4
2019 3
2020 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

97 results
Results by year
Filters applied: . Clear all
Page 1
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Gadde KM, et al. Lancet. 2011 Apr 16;377(9774):1341-52. doi: 10.1016/S0140-6736(11)60205-5. Epub 2011 Apr 8. Lancet. 2011. PMID: 21481449 Clinical Trial.
FINDINGS: Of 2487 patients, 994 were assigned to placebo, 498 to phentermine 75 mg plus topiramate 460 mg, and 995 to phentermine 150 mg plus topiramate 920 mg; 979, 488, and 981 patients, respectively, were analysed. At 56 weeks, change in bodyweight was -14 kg (le …
FINDINGS: Of 2487 patients, 994 were assigned to placebo, 498 to phentermine 75 mg plus topiramate 460 mg, and 995 to phentermine
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Allison DB, et al. Obesity (Silver Spring). 2012 Feb;20(2):330-42. doi: 10.1038/oby.2011.330. Epub 2011 Nov 3. Obesity (Silver Spring). 2012. PMID: 22051941 Free PMC article. Clinical Trial.
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine and topiramate (PHEN/TPM CR) for weight loss (WL) and metabolic improvements. ...
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine
A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.
Safer DL, Adler S, Dalai SS, Bentley JP, Toyama H, Pajarito S, Najarian T. Safer DL, et al. Int J Eat Disord. 2020 Feb;53(2):266-277. doi: 10.1002/eat.23192. Epub 2019 Nov 13. Int J Eat Disord. 2020. PMID: 31721257 Clinical Trial.
OBJECTIVE: Open trials suggest phentermine/topiramate ER (PHEN/TPM-ER), food and drug administration (FDA) approved for obesity, has utility for binge eating. ...
OBJECTIVE: Open trials suggest phentermine/topiramate ER (PHEN/TPM-ER), food and drug administration (FDA) approved for obesity, has …
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Garvey WT, et al. Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7. Am J Clin Nutr. 2012. PMID: 22158731 Free PMC article. Clinical Trial.
BACKGROUND: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with 2 w …
BACKGROUND: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle …
Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.
Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, Erondu N. Hollander P, et al. Diabetes Care. 2017 May;40(5):632-639. doi: 10.2337/dc16-2427. Epub 2017 Mar 13. Diabetes Care. 2017. PMID: 28289041 Clinical Trial.
OBJECTIVE: To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes. ...
OBJECTIVE: To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo …
A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. Weintraub M, et al. Arch Intern Med. 1984 Jun;144(6):1143-8. Arch Intern Med. 1984. PMID: 6375610 Clinical Trial.
We performed a double-blind, controlled clinical trial comparing phentermine resin (30 mg in the morning), fenfluramine hydrochloride (20 mg three times a day), and a combination of phentermine resin (15 mg in the morning) and fenfluramine hydrochloride (30 mg befor …
We performed a double-blind, controlled clinical trial comparing phentermine resin (30 mg in the morning), fenfluramine hydrochloride …
Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy.
Setnik B, McDonnell M, Mills C, Scart-Grès C, Robert P, Dayno JM, Schwartz JC. Setnik B, et al. Sleep. 2020 Apr 15;43(4):zsz252. doi: 10.1093/sleep/zsz252. Sleep. 2020. PMID: 31626696 Free PMC article. Clinical Trial.
METHODS: Nondependent, recreational stimulant users able to distinguish phentermine HCl 60 mg from placebo in a drug discrimination test were randomized in a four-period, double-blind, crossover design to receive single doses of pitolisant 35.6 mg (therapeutic dose), pitol …
METHODS: Nondependent, recreational stimulant users able to distinguish phentermine HCl 60 mg from placebo in a drug discrimination t …
Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.
Dalai SS, Adler S, Najarian T, Safer DL. Dalai SS, et al. Contemp Clin Trials. 2018 Jan;64:173-178. doi: 10.1016/j.cct.2017.10.007. Epub 2017 Oct 14. Contemp Clin Trials. 2018. PMID: 29038069 Clinical Trial.
Phentermine is FDA-approved for weight loss. A rationale for combined phentermine/topiramate for BED and BN is improved tolerability and efficacy. ...METHODS: Adults with BED (n=15) or BN (n=15) are randomized 1:1 to receive 12weeks Qsymia (phentermine/topira
Phentermine is FDA-approved for weight loss. A rationale for combined phentermine/topiramate for BED and BN is improved tolera
Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Aronne LJ, et al. Obesity (Silver Spring). 2013 Nov;21(11):2163-71. doi: 10.1002/oby.20584. Epub 2013 Oct 17. Obesity (Silver Spring). 2013. PMID: 24136928 Free article. Clinical Trial.
DESIGN AND METHODS: Subjects were randomized to placebo, phentermine 7.5 mg, phentermine 15 mg, topiramate ER 46 mg, topiramate ER 92 mg, PHEN/TPM ER 7.5/46 mg, or PHEN/TPM ER 15/92 mg. ...The percentage of subjects achieving 5% WL was 15.5% for placebo, 43.3% for …
DESIGN AND METHODS: Subjects were randomized to placebo, phentermine 7.5 mg, phentermine 15 mg, topiramate ER 46 mg, topiramat …
Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers.
Brauer LH, Johanson CE, Schuster CR, Rothman RB, de Wit H. Brauer LH, et al. Neuropsychopharmacology. 1996 Apr;14(4):233-41. doi: 10.1016/0893-133X(95)00113-R. Neuropsychopharmacology. 1996. PMID: 8924191 Clinical Trial.
Seven male and five female volunteers participated in an eight-session, double-blind study in which each subject received each of the following drug conditions: d-amphetamine (10 and 20 mg), phentermine (30 mg), fenfluramine (40 and 80 mg), phentermine (30 mg) with …
Seven male and five female volunteers participated in an eight-session, double-blind study in which each subject received each of the follow …
97 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page